TriSalus Updates 2026 Revenue Guidance Following Third Quarter Results
TriSalus (TLSI) reported third-quarter revenue of $12.9 million, marking an 11% year-over-year increase. Despite this growth, the company updated its full-year 2026 revenue guidance to a range of $46 million to $48 million, citing delays in sales representative productivity within new expansion territories and shifting treatment patterns. On the regulatory front, CMS finalized national pricing for PEDD embolization in office-based labs at approximately $13,788 per procedure. Additionally, the clearance of TriNav Advance allows for treatments in smaller blood vessels, expanding the company's addressable market. While sales execution remains a focus, improved gross margins of 86% and a strong cash position of $41 million provide a foundation for continued commercial expansion.
Topics: CMS reimbursement healthcare technology quarterly earnings revenue guidance